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Abstract
Rationale Brain 5-HT2C receptors form part of a neural net-
work that controls eating behaviour. 5-HT2C receptor agonists
decrease food intake by activating proopiomelanocortin
(POMC) neurons in the arcuate nucleus of the hypothalamus,
but recent research in rodents has suggested that 5-HT2C re-
ceptor agonists may also act via dopaminergic circuitry to
reduce the rewarding value of food and other reinforcers. No
mechanistic studies on the effects of 5-HT2C agonists on food
intake in humans have been conducted to date.
Objectives The present study examined the effects of the 5-
HT2C receptor agonist meta-chlorophenylpiperazine (mCPP)
on food consumption, eatingmicrostructure and blood oxygen
level-dependent (BOLD) functional magnetic resonance im-
aging (fMRI) responses to food pictures in healthy female
volunteers.
Methods In a double-blind, placebo-controlled, crossover de-
sign, participants were randomized immediately after screen-
ing to receive oral mCPP (30mg) in a single morning dose, or
placebo, in a counterbalanced order. Test foods were served
from a Universal Eating Monitor (UEM) that measured eating
rate and fMRI BOLD signals to the sight of food and non-food
images were recorded.
Results mCPP decreased rated appetite and intake of a palat-
able snack eaten in the absence of hunger but had no signifi-
cant effect on the consumption of a pasta lunch (although
pasta eating rate was reduced). mCPP also decreased BOLD
fMRI responses to the sight of food pictures in areas of
reward-associated circuitry. A post hoc analysis identified in-
dividual variability in the response to mCPP (exploratory
responder-non-responder analysis). Some participants did
not reduce their cookie intake after treatment with mCPP
and this lack of response was associated with enhanced ratings
of cookie pleasantness and enhanced baseline BOLD re-
sponses to food images in key reward and appetite circuitry.
Conclusions These results suggest that 5-HT2C receptor acti-
vation in humans inhibits food reward-related responding and
that further investigation of stratification of responding to
mCPP and other 5-HT2C receptor agonists is warranted.
Keywords 5-HT2C . Food consumption . BOLD fMRI
Introduction
Recent work on the neurophysiological basis of eating behav-
iour suggests that there are close interactions between the
homeostatic networks that respond to changes in metabolic
state and those involved in assigning reward value to motiva-
tional stimuli and translating motivation into action (Berthoud
2011). For example, food deprivation increases the incentive
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value of food, which is reflected in enhanced responses to
appetitive stimuli in reward-related brain areas whereas satia-
tion decreases responses in reward-related circuitry
(Goldstone et al. 2009; Thomas et al. 2015; see van der
Laan et al. 2011 for a meta-analysis). These effects are likely
to be mediated by the action of metabolic signals such as
leptin, insulin, peptide YY (PYY) and ghrelin on the activity
of the mesocorticolimbic dopamine system (Batterham et al.
2007; Guthoff et al. 2010; Farooqi et al. 2007; Malik et al.
2008).
The role of serotonin in the control of appetite has been
largely interpreted within a framework of homeostatic eating,
and the influence of hypothalamic cellular mechanisms in the
effects of serotonergic drugs on food intake is well document-
ed. The melanocortin system of the arcuate nucleus of the
hypothalamus (ARC) has been identified as a key network
in the anorectic effects of serotonin agonists, including the
5-HT2C receptor agonist lorcaserin, which has recently been
approved by the FDA to treat obesity (Heisler et al. 2002,
2006; Sohn et al. 2011). However, alterations in serotonin
transmission also affect reward-related circuits in the brain to
influence food intake, either directly (Aronson et al. 1995) or
indirectly via modulation of dopamine activity. Indeed, 5-
HT2C receptors expressed in the ventral tegmental area
(VTA) (Bubar and Cunningham 2007) modulate activity of
dopaminergic (DA) projections to the nucleus accumbens
(NAcc) to alter motivation for food and drug reinforcers in
rats (Fletcher et al. 2004; Higgins et al. 2013). These preclin-
ical data suggest a specific role for 5-HT2C receptor activation
in linking hypothalamic energy-sensing mechanisms to moti-
vational aspects of eating behaviour. However, to date, no
mechanistic studies on the effects of 5-HT2C receptor agonists
on food intake in humans have been reported.
Our aim here is to test the hypothesis that 5-HT2C receptor
activation reduces food-reward responses in humans. We in-
vestigate for the first time the effect of the preferential 5-HT2C
receptor agonist meta-chlorophenylpiperazine (mCPP) on he-
donic eating and neural responses to food images using func-
tional magnetic resonance imaging (fMRI). mCPP is known
to reduce appetite in humans (Cowen et al. 1995; Walsh et al.
1994; Thomas et al. 2014) but to probe reward-related effects
of mCPP, we examine the effect of mCPP on the consumption
of a staple meal consumed in a hungry state and a palatable
high-energy dense snack food eaten in the absence of hunger.
We also examine the microstructure of eating using a universal
eating monitor (UEM) to identify specific behavioural chang-
es that may underlie decreases in food intake (Thomas et al.
2014). We predicted that mCPP would reduce rated appetite
(Thomas et al. 2014), but that the drug effect on intake would
be greater for the palatable food consumed in the absence of
hunger than for the staple food consumed when hungry. We
also predicted that this effect of mCPP on palatable food con-
sumption might be mediated by a reduction in rated
pleasantness of the food and reflected in a reduction of
markers of neural activation in reward-related brain circuitry.
Materials and methods
Participants
Twenty-four women volunteers were recruited from the
University of Birmingham. Posters advertised the study as
an BAppetite & fMRI study ,^ and participants were compen-
sated with cash or course credits upon completion. The sample
sizewas based on the results of a previous study (Thomas et al.
2014). Ethical approval was provided by South Birmingham
Research Ethics Committee (National Research Ethics Service
number 11/WM/0411) and informed consent was provided by
all participants. Participants were screened to exclude the fol-
lowing: under 18 or over 65 years old, bodymass index (BMI)
under 18.5 or over 24.9 kg/m2, English not the first language,
taking any psychotropic medication or recreational drugs, past
or current Axis 1 disorder (determined by the Structured
Clinical Interview for DSM-IV Axis I Disorders; SCID-I/P;
Spitzer et al. 2004), pregnant or breastfeeding, smoker, dys-
lexic, food allergies, diabetic, cognitive dietary restraint score
higher than 10 as measured by the Three-Factor Eating
Questionnaire (TFEQ; Stunkard and Messick 1985).
Participants were also excluded if they had previously taken
part in a mCPP study, were left-handed or had any contrain-
dications to fMRI scanning. Women were asked to participate
in test days that fell outside their premenstrual week.
Design
In a double-blind, placebo-controlled, crossover design, par-
ticipants were randomized immediately after the screening
days to receive oral mCPP (30 mg) (Thomas et al. 2014) in
a single morning dose, or placebo, in a counterbalanced order.
mCPP and the matched placebo were supplied by the Guy’s
and St Thomas’ NHS Foundation Trust Pharmacy
Manufacturing Unit. The washout period between test ses-
sions was 7 days. To maintain blinding, mCPP and placebo
were prepared in identical capsules and unblinding occurred
on study completion. Peak plasma levels of mCPP are ob-
served 120–180 min after oral administration, which was
timed to coincide with the second fMRI scan.
Universal eating monitor
Food was served on a UEM consisting of a balance (Sartorius
Model CP4201, Sartorius Ltd., Epsom, UK; 0.1 g accuracy)
placed underneath the surface of a table and connected to a
laptop computer. A placemat hid the balance from view
(Thomas et al. 2014).
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Pasta Dishes filled with 220 g of pasta were provided. Each
time the participant ate 50 g of pasta, the Sussex Ingestion
Pattern Monitor (SIPM) software (version 2.0.13) interrupted
the participant to complete computerised visual analogue scale
(VAS) ratings (hunger, fullness and pleasantness of the pasta).
After consuming 150 g, participants were interrupted and pro-
vided with a fresh dish of 220 g of pasta. Participants were
asked to eat in this manner until they felt ‘comfortably full’.
The lunch consisted of pasta shells in a tomato and herb sauce
served at 55–60 °C (207 kcal per 220-g serving).
Cookies Bowls containing 80 g of cookie pieces were provid-
ed. Each time the participant ate 10 g of cookie pieces, the
SIPM software interrupted the participant to complete VAS
ratings as described above. After consuming 60 g, participants
were interrupted and provided with a fresh bowl containing
80 g of cookie pieces. Participants were asked to eat until they
felt ‘comfortably full’. The cookies were Maryland Chocolate
Chip Cookies, with each cookie being broken into 6–7 pieces
(390 kcal per 80-g serving).
Salivary cortisol assessment
Salivary cortisol was collected to confirm a pharmacological
response to mCPP administration (Meltzer and Maes 1995)
and was measured by liquid chromatography–mass spectrom-
etry (LC–MS/MS) as described previously (Thomas et al.
2014).
Procedure
The experimental procedure is summarised in Fig. 1.
Screening days Participants who met the study criteria were
invited to a screening day at which they completed: a medical
screening sheet, the Eysenck Personality Questionnaire (EPQ;
Eysenck and Eysenck 1975) and a questionnaire to determine
whether they usually consume lunch. Height and weight were
also taken to calculate BMI. Participants returned after a week
for two practice sessions, both a week apart, with the UEM.
Test days Participants arrived having consumed their normal
breakfast. If they passed a medical examination (first day
only), they were breathalysed and completed a pregnancy test,
before completing the first batch of questionnaires to assess
what and when they had eaten that morning, and several mea-
sures to assess mood: Beck Depression Inventory (BDI; Beck
et al. 1961); Befindlichskeit Scale of mood and energy (BFS;
von Zerssen et al. 1974); Positive and Negative Affect
Schedule (PANAS; Watson et al. 1988); and State-Trait
Anxiety Inventory (STAI; Spielberger 1983). They also com-
pleted the Power of Food Scale (PFS, Lowe et al. 2009), and
the Barratt Impulsivity Scale (BIS—Patton et al. 1995) and
baseline VAS to assess the following: ‘alertness’; ‘disgust’;
‘drowsiness’; ‘light-headed’; ‘anxiety’; ‘happiness’; ‘nausea’;
‘sadness’; ‘withdrawn’; ‘faint’; ‘hungry’; ‘full’; ‘desire to eat’;
and ‘thirst’.
A baseline fMRI scan was then conducted, after which
participants completed the VAS, provided a saliva sample
and took either mCPP or placebo. At 30 min post-dosing, they
completed another set of VAS. Thirty minutes later, partici-
pants provided a saliva sample and completed VAS. They
were scanned again and then completed a set of VAS and
provided another saliva sample.
Immediately before lunch, participants completed VAS and
were given ad libitum access to a pasta lunch via the UEM.
After lunch, participants completed VAS followed by a 20-
min break, after which a further set of VAS was completed
before participants were given ad libitum access to a cookie
snack. Immediately after the snack, participants filled out
VAS. Approximately 30–40 min later, participants completed
a second batch of questionnaires: VAS, BDI, BFS, PANAS,
STAI, PFS and BIS and provided a final saliva sample, rated
the scanner task food images and had a single blood sample
taken. At the end of their second session, participants were
fully debriefed, thanked for their time and reimbursed for
participation.
Imaging task
The scanner task was based on that used by Allen et al. 2016.
There were three separate blocks in which participants viewed
40 food pictures (20 high-calorie food images and 20 low-
calorie food images), 40 non-food control pictures and 5 smil-
ey face images in three separate blocks. The high-calorie im-
ages (mean number of calories per 100 g of food shown = 365)
Fig. 1 Flow diagram for screening process followed by an overview of key events and timings for test days in hours (hrs)
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and low-calorie images (mean number of calories per 100 g of
food shown = 79) were comparable with previously published
tasks (Goldstone et al. 2009). The pictures were displayed for
2500 ms, fixation points were displayed for 3500 ms and
smiley face images were displayed for 1500 ms. Participants
were asked to pay attention to all images, but to imagine eating
the foods they saw during the task, and to press a button on a
button box when they saw a smiley face to ensure they were
maintaining attention.
fMRI data acquisition and analysis
An event-related design was used, in which the stimuli were
presented in pseudo random sequence. The scanner was a
3.0 T Achieva (Philips) whole body scanner with an eight-
channel head coil. T2*-weighted echo planar imaging (EPI)
slices were acquired every 2.5 s (TR = 2.5). Thirty-three axial
slices with an in-plane resolution of 2.5 × 2.5 × 3 mm2 and
slice thickness of 3 mm (no gap) were acquired, with a matrix
size of 96 × 96 and field of view of 240 × 240 mm.
Acquisition angulation was consistently AC-PC. Two hun-
dred volumes were acquired for each block of the task with
two dummy scans which were discarded prior to any analysis.
A whole brain T2*-weighted EPI volume (resting state) was
also acquired (AC-PC angulation), along with an anatomic
T1-weighted volume acquired in the sagittal plane slice thick-
ness of 1 mm and in-plane with a reconstructed resolution of
1.0 × 1.0 × 1.0 mm. The FMRIB software library (FSL;
FMRIB, Oxford, www.fmrib.ox.ac.uk/fsl) was used for pre-
processing and data analyses. Pre-processing involved high-
pass filter cutoff of 60 s; motion correction using FMRIB’s
Linear Image Registration Tool (MCFLIRT); motion parame-
ters as regressors of no interest; interleaved slice timing cor-
rection; spatial smoothing with a 6-mm full-width-half-
maximum kernel; high-pass temporal filtering and FILM
pre-whitening. Functional data were registered to their corre-
sponding structural images and transformed to Montreal
Neurological Institute (MNI) space using a reference brain
(12 DOF linear transformation). Multivariate Exploratory
Linear Optimized Decomposition into Independent
Components (MELODIC) was used to remove artefacts (these
comprised 2% of all MELODIC components).
Analysis 1: effect of task
MELODIC filtered data were entered into a first-level analy-
sis, to produce contrast of parameter estimate (COPE) images
for blood oxygen level-dependent (BOLD) response to food
and control images separately. Mean BOLD % signal change
(unthresholded) was extracted with Featquery using masks of
a priori regions of interest (ROI) selected from standard tem-
plates from WFUPickatlas (Maldjian et al. 2003). The ROIs
chosen were based on previous neuroimaging work (see
Supplemental Table 1 for list of ROIs and supporting
references). The BOLD % signal change to food and control
images was compared using paired sample t tests using IBM
SPSS (version 23). Bonferroni correction was applied to con-
trol for the family-wise error (FWE).
Analysis 2: effect of placebo versus mCPP on BOLD
signals to high- and low-calorie foods
MELODIC filtered data were entered into a first-level analy-
sis, to produce COPE images for high-calorie and low-calorie
food images, minus the BOLD response to the corresponding
control images. These COPEs were averaged across each of
the scanning blocks for each participant. A subsequent analy-
sis was run on these outputs for each participant to subtract
baseline scans from post-dosing scans. The outputs were en-
tered into the final mixed effects (FLAME 1 + 2) group anal-
ysis, producing contrasts between placebo and mCPP condi-
tions for BOLD signal activity in response to the high-calorie
food images and the low-calorie food images separately.
Group Z statistic images were corrected for multiple com-
parisons by FWE correction using AlphaSim, part of the
AFNI toolkit (Cox 1996) (AFNI Version 16.1.16—May 25,
2016). With a voxel-wise threshold of p < 0.005 (Z > 2.6),
only clusters with more than 24 contiguous voxels were sig-
nificant with a FWE rate corrected p < 0.05.
CovariatesAnalysis 2 above was repeated with mean centred
VAS ratings (taken immediately prior to each scan) of nausea,
light-headed and faint entered as covariates (separately) to
account for any non-specific effects of mCPP on the BOLD
response to food images.
Data analysis
Main effects and interactions with condition were examined
with analysis of variance (ANOVA). Bonferroni correction
was used on all follow-up t tests unless otherwise stated.
Data loss Data were lost for seven pasta sessions and two
cookie sessions due to technical issues, such as participants
leaning on the balance. In addition, one participant did not
return for the second session.
Results
Participant characteristics
The sample comprised young women (mean age = 22.7
(SEM: 1.19)) with a lean BMI (mean BMI = 21.8 (SEM:
0.32)). TFEQ scores were as follows: cognitive restraint
(mean = 5.77 (SEM: 0.49)), disinhibition (mean = 7.1
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(SEM: 0.78)) and hunger (mean = 6.5 (SEM: 0.84)).
Participant questionnaire scores on the BDI, BIS-11, BFS,
PFS, PANAS and STAI are summarised in Supplemental
Table 2.
Salivary cortisol
Cortisol levels at baseline and immediately prior to the test
meal were analysed with ANOVA: there were no main effects
of condition (F (1 22) = 4.03; p = 0.06) or time (F (1
22) = 0.75; p = 0.4), but a significant interaction between
condition and time (F (1 22) = 8.85; p = 0.007). There were
no baseline differences between mCPP and placebo condi-
tions (4.98 vs. 5.59 nmol/L; t (22) = − 1.14, p = 0.3); however,
immediately prior to food, cortisol was significantly higher in
the mCPP than the placebo condition (6.62 vs. 2.77 nmol/L; t
(22) = − 2.62, p = 0.03).
Appetite and mood ratings
Baseline VAS ratings did not differ according to condition (all
ps > 0.05—data not shown). t tests on area under the curve
scores (AUC—trapezoid method) showed increased scores in
the mCPP condition relative to placebo for faint (2254.13 vs.
706.30; t (22) = − 3.05, p = 0.006), light-headed (2938.26 vs.
751.09; t (22) = − 5.09, p = 0.00004) and nausea (2158.04 vs.
606.09; t (22) = − 5.27, p = 0.00003) along with decreased
hunger (6595.30 vs. 8172.39; t (22) = 2.11, p = 0.047) and
desire to eat (6168.04 vs. 7830.65; t (22) = 2.10, p = 0.048).
There were no other significant effects of condition nor any
interactions (all p > 0.05) (Supplemental Table 3).
UEM measures
PastaRate of pasta consumption was significantly reduced by
mCPP (t (16) = 2.27, p = 0.04), and pauses between mouthfuls
increased (t (16) = −2.32, p = 0.03, Fig. 2). There was no main
effect of drug for total amount eaten (t (16) = 1.43, p = 0.2) or
time spent eating (t (22) = 1.43, p = 0.2).
Cookies In the mCPP condition, participants ate fewer cook-
ies (t (20) = 3.09, p = 0.006), at a slower rate (t (18) = 4.12,
p = 0.0004), and took longer pauses between mouthfuls com-
pared with the placebo condition (t (18) = − 3.82, p = 0.001
(Fig. 2)). No significant differences were observed for total
time spent eating (t (20) = − 0.98, p = 0.4).
Within-meal VAS pleasantness ratings mCPP tended to re-
duce rated pleasantness of the pasta (t (16) = 1.99, p = 0.06;
68.79 mm for mCPP vs. 73.97 mm for placebo). The cookies
were rated as less pleasant after mCPP relative to placebo (t
(19) = 2.46, p = 0.02; 78.36 vs. 84.84 mm).
Correlations between hunger, nausea and intake After
mCPP, pasta intake was significantly positively correlated
with hunger (r = 0.52, n = 19, p < 0.05); pasta intake was
not correlated with either rated nausea, light-headedness or
sensations of faint (all ps > 0.05). Cookie intake after mCPP
did not correlate with hunger, nausea, light-headed nor faint
(all ps > 0.05). In addition, including a composite measure of
nausea, light-headed and faint ratings as a covariate in the
analyses did not affect the pattern of results for consumption
of pasta or cookies.
fMRI
Main effect of task
The following regions showed a significantly greater BOLD
response to food compared to control images: nucleus accum-
bens, midbrain, orbitofrontal cortex, ventromedial prefrontal
cortex, insula, amygdala, cingulate cortex (anterior and poste-
rior), dorsal striatum (caudate and putamen) and dorsolateral
prefrontal cortex (inferior and middle frontal gyrus) (all p-
s < 0.05—Supplemental Table 1). Additional follow-up anal-
ysis comparing responses to high-calorie versus low-calorie
pictures revealed no significant differences according to pic-
ture type (data not shown).
Placebo versus mCPP contrast
High-calorie foods mCPP attenuated activity in the left dor-
solateral prefrontal cortex (dlPFC), right dlPFC, right anterior
cingulate cortex (ACC), left and right insula, right caudate and
left midbrain, while increasing activity in the right ventrome-
dial prefrontal cortex (vmPFC) (Fig. 3 and Table 1).
Low-calorie foods mCPP attenuated activity in the left and
right dlPFC, left and right insula, and left ACC, while increas-
ing activity in the left and right vmPFC, left hippocampus, left
parahippocampal gyrus and left amygdala (Fig. 3 and
Table 1).
Covariates Including either nausea, light-headed or faint rat-
ings in the analyses did not affect either the direction or the
significance of any of the local maxima reported here (Z
scores for all local maxima remained equal to or greater than
the threshold of p < 0.005).
Post hoc analysis: responders versus non-responders
Inspection of the intake data revealed that some participants ate
less after mCPP but others showed no response, or an increase
in intake. Participants were classified as responders if they
showed a > 10% decrease in cookie consumption after mCPP
versus placebo, and non-responders if they showed a < 10%
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decrease in consumption after mCPP versus placebo (12 re-
sponders and 8 non-responders). Analysis was conducted on
cookie intake and restricted to responses to high-calorie food
images becausemCPP had a significant effect on cookie but not
pasta intake.
Responder versus non-responder characteristics
Responders and non-responders did not differ in terms of ba-
sic characteristics (age, BMI and TFEQ subscales) or baseline
questionnaire and VAS scores averaged across both test ses-
sions (all ps > 0.05—see Supplemental Table 4). While pre-
cookie hunger ratings were not significantly different between
responders and non-responders (21.6 vs. 21.1 mm; t
(16) = − 0.05, p > 0.05), the non-responder group rated
cookies as significantly more pleasant than the responder
group (85.3 vs. 70.9 mm; (t (16) = 2.27, p < 0.05).
Baseline BOLD responses
Baseline scan data were pre-processed as described above in
analysis 1. The data from pre-mCPP and pre-placebo baseline
scans were averaged. The outputs were entered into a mixed
effects model, to produce contrasts between non-responders
and responders for BOLD signal activity in response to high-
calorie foods. Non-responders showed a greater BOLD re-
sponse than responders in the right dorsolateral prefrontal cor-
tex, right brain stem, left brain stem, right insula and right
putamen. Responders showed a greater response than non-
responders in the vmPFC, right insula and left dorsolateral
prefrontal cortex (Fig. 4; local maxima in Table 1).
Fig. 2 Universal eating monitor measures for the pasta lunch (a) and
cookie snack (b) split by placebo and mCPP conditions. mCPP
significantly reduced the consumption of cookies but not pasta. For
both foods, mCPP significantly increased the pause between mouthfuls
and reduced the eating rate (amount eaten per minute). Time spent eating
was not significantly different for either food after dosing with mCPP.
*p < 0.05; **p < 0.01; ***p < 0.001
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Discussion
The 5-HT2C receptor agonist mCPP increased salivary cortisol
confirming activation of 5-HT2C receptors. mCPP decreased
intake of cookies eaten in the absence of hunger but had no
effect on the amount of a pasta lunch consumed, although the
pasta eating rate was reduced. mCPP also decreased BOLD
responses to the sight of food pictures in reward-associated
circuitry. These data suggest a role for 5-HT2C receptor acti-
vation in mediating reward-related responses to food in
humans.
Consistent with the present findings, Thomas et al. (2014)
reported that mCPP did not reduce pasta intake but reduced
rated appetite. By contrast, mCPP reduced intake of cookies
and blunted the rated pleasantness of cookies. The effect of
mCPP on microstructural measures of eating was also greater
for cookie than for pasta consumption. Thirty milligrams of
mCPP reduced the rate of pasta consumption by 26% and cook-
ie consumption by 39% and increased the duration of pauses
between mouthfuls of pasta and cookies by 49 and 109%, re-
spectively. Taken together, these data suggest that the effect of
mCPP on appetite was greater for the cookies than for the pasta.
Fig. 3 BOLD response to high-
and low-calorie food images (a
and b, respectively). Orange de-
picts brain areas where the BOLD
response was greater after dosing
with mCPP compared to placebo
whereas blue depicts brain areas
where participants show a greater
BOLD response when dosed with
placebo compared to mCPP. L
left, R right, dlPFC dorsolateral
prefrontal cortex, IFG inferior
frontal gyrus,MFGmiddle frontal
gyrus, ACC anterior cingulate
cortex, IFG inferior frontal gyrus,
vmPFC ventromedial prefrontal
cortex
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mCPP increased ratings of nausea-like symptoms but these
ratings were not correlated with food intake, suggesting they
were unlikely to account for the effects on eating behaviour, as
shown previously (Walsh et al. 1994; Thomas et al. 2014). In
addition, the differential effects of mCPP on pasta and cookie
intake suggest that these effects are not secondary to nausea
which would be expected to suppress intake of both foods to a
similar extent.
It is not possible to conclude whether the effects of mCPP
were related to the greater palatability of the cookies, their
greater energy density or both. Indeed, there are several dif-
ferences between the pasta and cookies, including their sen-
sory characteristics that might explain the pattern of results. In
addition, the cookies were served after a satiating meal, and it
may be that the effects of mCPP are enhanced under condi-
tions of satiety. 5-HT2C receptors may mediate reductions in
food reward that occur as food is consumed, known as
alliesthesia (Cabanac 1971). It will be important to test this
hypothesis because reductions in reward-related responding
that are specific to the satiated state are likely to be effective
in helping individuals to curb their appetite but are unlikely to
reduce hedonic responding in general as observed for the
withdrawn anti-obesity drug rimonabant (Butler and
Korbonits 2009). Such investigations are also likely to shed
light on the role of background neural activity and experimen-
tal context in the effects of 5-HT2C receptor stimulation on
reward-related behaviour (Vollm et al. 2010).
mCPP attenuated BOLD activity to the sight of both high
and low food images in a number of brain regions involved in
reward including the insula, anterior cingulate cortex,
dorsolateral prefrontal cortex and caudate (Wang et al. 2008;
Holroyd and Yeung 2012; Morris et al. 2014). This pattern of
results was not affected by adding nausea-like ratings as a
covariate in the analysis suggesting that the results are not
explained by negative side effects of the drug. 5-HT2C recep-
tors are located in the prefrontal cortex, cingulate cortex and
the caudate (Pazos et al. 1987; Pompeiano et al. 1994;
Marazziti et al. 1999), suggesting that mCPP may act in these
areas to affect responding to food stimuli. Areas showing in-
creased activation after mCPP versus placebo were limited to
the vmPFC, hippocampus, parahippocampal gyrus and amyg-
dala. It has been proposed that activity in the vmPFC and
dlPFC is associated with context-dependent value-based
decision-making and selective attention to motivationally rel-
evant stimuli and the pattern of BOLD activity observed could
suggest that the influence of contextual factors, such as meta-
bolic state, on food valuation is altered by mCPP (Rudorf and
Hare 2014; Walton et al. 2015). Since we found a stronger
anorectic response after mCPP when eating in the absence of
hunger, it would be of interest to examine whether the effect of
mCPP on BOLD responses is dependent upon levels of satiety.
There was no effect of mCPP on hypothalamic responses
but we draw no strong conclusion about this null effect be-
cause the hypothalamus is difficult to image and is susceptible
to artefacts due to its proximity to the sinuses (Ojemann et al.
1997), which might also explain the lack of a main effect of
task for hypothalamic responding. A recent study of the ef-
fects of lorcaserin on BOLD responses to food pictures in
participants with obesity similarly failed to find an effect on
hypothalamic activation (Farr et al. 2016). However,
Fig. 4 Baseline BOLD response to high-calorie food images. Orange
depicts brain areas where non-responders show a greater BOLD response
than responders; blue depicts brain areas where responders show a greater
BOLD response than non-responders. L left, R right, VTA ventral teg-
mental area, dlPFC dorsolateral prefrontal cortex, MFG middle frontal
gyrus, IFG inferior frontal gyrus, vmPFC ventromedial prefrontal cortex
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Table 1 Local maxima of key
appetitive and reward areas
showing (A) main effect of con-
dition (placebo vs. mCPP), split
by activity to high- and low-
calorie food images and (B) dif-
ferences in BOLD signal between
non-responders and responders at
baseline to the sight of high-
calorie food images
Brain region (hemisphere) Montreal
Neurological Institute
(MNI) coordinates
Brodmann
area
Z score
X Y Z
A. Main effect of condition
Reduced activation after mCPP (compared to placebo)
High-calorie food images
dlPFC (middle frontal gyrus)/precentral gyrus (L) − 30 − 6 54 6 5.2
Anterior cingulate rortex (R) 4 22 30 24 3.3
Insula (L) − 38 10 − 14 48 3.3
Caudate (R) 14 − 2 24 – 3.1
dlPFC (middle frontal gyrus) (R) 38 6 58 6 3.0
dlPFC (inferior frontal gyrus) (R) 54 28 0 45 2.8
Insula (R) 42 − 10 0 48 2.8
Midbrain (L) − 8 − 14 − 4 – 2.7
Low-calorie food images
dlPFC (inferior frontal gyrus) (L) − 52 26 20 45 3.9
dlPFC (inferior frontal gyrus) (R) 52 32 16 48 3.9
dlPFC (middle frontal gyrus) (L) − 36 − 2 62 6 3.6
dlPFC (middle frontal gyrus) (R) 36 26 42 9 3.5
Insula (L) − 42 − 8 2 48 3.4
Insula (R) 40 − 14 0 48 3.3
Anterior cingulate cortex (L) − 4 26 28 24 3.1
Increased activation after mCPP (compared to placebo)
High calorie
Ventromedial prefrontal cortex (R) 26 52 − 12 11 3.1
Low calorie
vmPFC (L) − 14 62 − 16 11 3.3
Parahippocampal gyrus (L) − 20 − 26 − 22 30 3.2
Hippocampus (L) − 28 − 14 − 20 20 3.2
Amygdala (L) − 22 − 6 − 18 34 3.1
vmPFC (R) 12 60 − 18 11 2.8
B. Responders versus non-responders
Non-responders > responders
Dorsolateral prefrontal cortex (inferior frontal gyrus) (R) 52 12 30 44 4.4
Dorsolateral prefrontal cortex (middle frontal gyrus) (R) 54 14 44 44 4.0
Brainstem (midbrain–ventral tegmental area) (R) 4 − 16 − 14 – 3.6
Brainstem (midbrain–red nucleus) (L) − 4 − 20 − 12 – 3.5
Insula (superior/anterior) (R) 32 22 8 48 3.4
Putamen (R) 24 14 0 48 3.1
Responders > non-responders
Ventromedial prefrontal cortex 0 54 − 12 11 3.7
Insula (superior/posterior) (R) 38 − 8 6 48 3.6
Dorsolateral prefrontal cortex (inferior frontal gyrus) (L) − 50 26 2 45 3.6
Parahippocampal gyrus/hippocampus (R) 18 − 10 − 26 28 3.5
FWE cluster corrected (voxel p < 0.005; cluster > 24 contiguous voxels—p < 0.05)
L left side, R right side
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participants who received lorcaserin twice a day showed less
activation in insula, parietal cortex, visual cortices, hippocam-
pus and amygdala in the fasting state at 1 than 4 weeks.
Although the study of Farr et al. (2016) is not directly com-
parable to the present study, due to several methodological
differences between the studies, the data suggest that there is
some overlap between the effects of mCPP and lorcaserin on
responding to food pictures in the short term, which could
point towards common 5-HT2C receptor-mediated effects.
An exploratory post hoc analysis examined apparent indi-
vidual variability in response to mCPP. At baseline, partici-
pants who did not respond to mCPP by decreasing their intake
of cookies showed greater BOLD activity than responders in
areas including dorsolateral prefrontal cortex, insula and pu-
tamen andmidbrain. After dosing with mCPP, non-responders
rated cookies as more pleasant than responders, in the absence
of differences in rated hunger suggesting that heightened re-
ward response might be responsible for blunting the
hypophagic effect of mCPP. Further investigation of the char-
acteristics of responders versus non-responders is required,
but our results suggest that imaging data may shed light on
which individuals are likely to show reduced food intake after
treatment with 5-HT2C receptor agonists.
We provide the first evidence that mCPP reduces consump-
tion of a palatable energy dense snack in humans. mCPP also
caused a marked reduction in neural activity across reward-
related brain regions to the sight of food. An implication of
these findings is that 5-HT2C receptor agonists such as
lorcaserin may be effective in helping individuals to reduce
their intake of palatable food in the absence of hunger. In
addition, we found that some participants did not reduce their
cookie intake after treatment with mCPP and this was associ-
ated with enhanced rated cookie pleasantness and enhanced
baseline BOLD responses to food in key reward areas. Further
investigation of stratification of responding to mCPP (and
potentially other 5-HT2C receptor agonists such as lorcaserin)
is required to identify patients who are more likely to respond
to weight management drugs that act at the 5-HT2C receptor
and hence more effectively target therapy.
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